30 closest matches · ranked by relevance
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Lymphoma
Primary: Progression-free Survival at 1 Year — 38 percentage of participants
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Lymphoma
Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Ann Arbor Stage II Grade 1 Follicular Lymphoma · Ann Arbor Stage II Grade 2 Follicular Lymphoma · Ann Arbor Stage III Grade 1 Follicular Lymphoma
Primary: Progression Free Survival — 70.7 months
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma · Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Primary: Number of Participants Who Achieved a Complete Response — 47 Participants
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Follicular Lymphoma
Primary: Number of Participants With Overall Response Rate (ORR) — 0; 0; 0; 0 participants
Lymphoma
Primary: Overall Response Rate (Complete or Partial Response) by Month 12 — 60; 84 percentage of patients
Lymphoma
Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Follicular Lymphoma · Non-Hodgkin's Lymphoma Follicular · Non-Hodgkin's Lymphoma, Adult High Grade
Primary: Complete Response (CR) at End of Induction — 41; 11; 1; 0 Participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Lymphoma
Primary: Event-free Survival — 76 percentage of patient
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Lymphoma, Non-Hodgkin
Primary: Number of Participants Who Received the Therapeutic Dose at the Seven Clinical Research Sites — 7; 8; 8; 5 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
Lymphoma
Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose) — 6; 1…
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Lymphoma
Primary: Complete Response Rate — 23 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants
Lymphoma
Primary: Complete Remission (CR) Rate — 0.62; 0.75 proportion of participants — p=0.02
Lymphoma, Follicular
Primary: Number of Participants With Complete Response at 3 Years — 30 Participants
Non-Hodgkin's Lymphoma
Primary: Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab — 83.1; 134.6 micrograms per milliliter (mcg/mL)